Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago

McDonald, AC and Jenkins, FJ and Bunker, CH and Wilson, JW and Patrick, AL and Weissfeld, JL (2011) A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago. Infectious Agents and Cancer, 6 (1).

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (456kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

Background: We previously reported a cross-sectional association between the presence of human herpesvirus 8 (HHV-8) serum antibodies and screen-detected prostate cancer in men living in Tobago. In the same study population, we examined the association between HHV-8 seropositivity and incident prostate cancer discovered at later screenings. Methods. In 40-81 year-old men without prostate cancer discovered at initial digital rectal examination (DRE) and prostate-specific antigen (PSA) screening, a case-cohort design measured the association between baseline HHV-8 seropositivity (modified immunofluorescence assay for antibodies against HHV-8 lytic antigens) and incident prostate cancer detected at DRE and PSA screenings three or five years later. Results: Analyses included 486 unique individuals, 96 incident prostate cancer cases, and 415 randomly selected subjects representing an at-risk cohort. By design, the random sub-cohort contained 25 incident prostate cancer cases. In the sub-cohort, the frequency of HHV-8 seropositivity increased across age groupings (40-49 years: 3.5%, 50-59 years: 13.6%, and ≥ 60 years: 22.9%). HHV-8 seropositivity was higher in men with elevated (≥ 4.0 ng/mL) than men with non-elevated PSA at initial screening (30.4% vs. 9.9% seropositive; crude odds ratio (OR) 3.96, 95% confidence interval (CI) 1.53-10.2; age-adjusted OR 2.42, 95% CI 0.91-6.47). HHV-8 seropositivity did not increase incident prostate cancer risk (age-adjusted hazard ratio (HR) 0.88, 95% CI 0.46-1.69). Conclusions: Case-cohort analysis did not identify association between HHV-8 seropositivity and incident prostate cancer. However, analyses uncovered possible association between HHV-8 and PSA (a marker of prostate inflammation). Co-occurrence of HHV-8 seropositivity and PSA elevation may explain cross-sectional association between HHV-8 and PSA screen-detected prostate cancer. © 2011 McDonald et al; licensee BioMed Central Ltd.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
McDonald, AC
Jenkins, FJfjenkins@pitt.eduFJENKINS
Bunker, CHBUNKERC@pitt.eduBUNKERC
Wilson, JWjww@pitt.eduJWW
Patrick, AL
Weissfeld, JL
Centers: Other Centers, Institutes, Offices, or Units > Pittsburgh Cancer Institute
Date: 8 December 2011
Date Type: Publication
Journal or Publication Title: Infectious Agents and Cancer
Volume: 6
Number: 1
DOI or Unique Handle: 10.1186/1750-9378-6-25
Schools and Programs: Graduate School of Public Health > Biostatistics
Graduate School of Public Health > Epidemiology
School of Medicine > Pathology
Refereed: Yes
Date Deposited: 01 Nov 2016 16:47
Last Modified: 30 Oct 2018 13:56
URI: http://d-scholarship.pitt.edu/id/eprint/29989

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item